Question-and-Answer Session
Operator
(Operator instructions) And our first question will come from Kim Lee with Pacific Growth.
Kim Lee – Pacific Growth
Good afternoon. Two questions for you. First have you had your end of phase II meeting with the FDA yet with regards with Huntington's disease?
Lynn Seely
We have not had that meeting yet.
Kim Lee – Pacific Growth
Okay. And when do you plan to have that meeting?
Lynn Seely
I cannot assure you that it is soon as we results from that meeting we will share it with you, but I cannot tell you at this point exactly when the meeting is going to be.
Kim Lee – Pacific Growth
Okay. Second question is how many additional studies do you intend to run at your safety database [ph]?
Lynn Seely
We are really in the process of making final decisions about that. There are lots of options for this drug as you might imagine it has a lot of potential and so we are considering a host of options from – evaluated in the presence of other standard of care medications to diseases of increasing severity or more moderate-to-severe disease et cetera. So, we do not have the final plans but when we do we will be bringing those forward to you.
Kim Lee – Pacific Growth
On the QTc study that you just completed how many patients were in that and is [inaudible] so patients won’t be included in the safety database as well?
Lynn Seely
All patients who have been treated with the drug will be included there were 150 patients in that study, 50 of them were treated with Dimebon.
Kim Lee – Pacific Growth
Okay, thanks a lot.
Operator
Thank you. Our next question will come from Michael Yee with RBC Capital Markets.
Michael Yee – RBC Capital Markets
Hi, guys. A couple of questions in regards to MDV3100 you said you are going up a couple of more cohorts. Are we going to see final data by year-end is that going to be press released and presented, and then would you continue to go higher if you didn’t see an MTD?
Lynn Seely
So, we are we have not yet achieved an MTD, so we are continuing to dose escalate. I think, obviously we are very intent on moving that program forward. So, I don’t think you will see us continue to dose escalate. And we are intending to complete the study by the end of the year.
- To read the full transcript on Seeking Alpha, click here »
